Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading." [View news story]
Pluristem – check your rear-view mirror – why did so many “opine” and react to the Bloomberg article? In the cell therapy universe, PSTI’s more than often “hyperbole” style has by turns been admired and derided. The “walls of reality” closed in … does this “on slot” of written matter talk about their relationships to the “street” and to the reporting thus, “transparency” is the ultimate vehicle … no matter what one does – there is a population of investors that are “moved” by perception! Maybe, there is a lesson here but, the damage is done!
Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading." [View news story]
Regenerative Medicine Companies Trading At Huge Discounts [View article]
Henry
Cytori Therapeutics: Don't Buy In to the Momentum [View article]